~~<i id='0BE8D7920F'><strike id='0BE8D7920F'><tt id='0BE8D7920F'><pre id='0BE8D7920F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：comprehensive 2025-09-30 17:30:08 - browse：69

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Idaho college killings prosecutors challenge defense's grand jury claims

hotspot

entertainment

leisure time

explore

hotspot

AdobeI’mstandingoveranoperatingtable,excisingaskincancerfromtheforeheadofanelderlygentlemanwhilesoft

WSS

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

FDA early review: GLP

Hospital chaplains balance Covid safety with patients’ spiritual needs

Biden administration begins canceling student loan debt for 804,000 borrowers

Idaho college killings prosecutors challenge defense's grand jury claims

Patients, digital health players weigh in on FTC's data privacy plan

knowledge

fashion

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Aspartame and sugar

New air purifier tech could be key to improving indoor air quality

Biogen’s boardroom scandal saddles CEO with first crisis

Medical leaders decry Supreme Court decision on affirmative action

After Optum profits sink, UnitedHealth makes changes

In age of alternative facts, a scholarly course on calling out crap

After Optum profits sink, UnitedHealth makes changes

As demand for Covid shots wanes, Moderna seeks its next success

Hospital chaplains balance Covid safety with patients’ spiritual needs

entertainment

Hospital chaplains balance Covid safety with patients’ spiritual needs

Maui wildfire now ranks as the fifth

Biogen’s boardroom scandal saddles CEO with first crisis

Senators push IRS to launch nonprofit hospital probe

Medicare Advantage coverage denials need scrutiny, senators say

Boston Scientific acquires urology company Axonics for $3.7 billion

leisure time

explore

hotspot

hotspot